"Chemokine CXCL10" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR.
| Descriptor ID |
D054357
|
| MeSH Number(s) |
D12.644.276.374.200.120.500 D12.776.467.374.200.120.500 D23.125.300.120.500 D23.469.200.120.500 D23.529.374.200.120.500
|
| Concept/Terms |
Chemokine CXCL10- Chemokine CXCL10
- CXCL10, Chemokine
- Cytokine IP-10 Protein
- Cytokine IP 10 Protein
- IP-10 Protein, Cytokine
- Interferon-Inducible Protein 10
- Interferon Inducible Protein 10
- CXC Chemokine IP-10
- CXC Chemokine IP 10
- Chemokine IP-10, CXC
- Small Inducible Cytokine B10
- IFN-gamma-Inducible Protein, 10 kDa
- IFN gamma Inducible Protein, 10 kDa
- CXCL10 Chemokine
- Chemokine, CXCL10
- gammaIP-10 Protein
- gammaIP 10 Protein
- Chemokine (C-X-C Motif) Ligand 10
- Interferon-gamma-Inducible Protein of 10 kDa
- Interferon gamma Inducible Protein of 10 kDa
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL10".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL10".
This graph shows the total number of publications written about "Chemokine CXCL10" by people in this website by year, and whether "Chemokine CXCL10" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 4 | 4 |
| 2007 | 1 | 2 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 2 | 4 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL10" by people in Profiles.
-
Tang Q, Sousa J, Echeverria D, Fan X, Hsueh YC, Afshari K, MeHugh N, Cooper DA, Vangjeli L, Monopoli K, Okamura K, Biscans A, Clauss A, Harris JE, Khvorova A. RNAi-based modulation of IFN-? signaling in skin. Mol Ther. 2022 08 03; 30(8):2709-2721.
-
Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc Natl Acad Sci U S A. 2021 07 27; 118(30).
-
Riding RL, Richmond JM, Fukuda K, Harris JE. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. Pigment Cell Melanoma Res. 2021 07; 34(4):683-695.
-
Groover MK, Richmond JM. Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases. F1000Res. 2020; 9:1197.
-
Lee MH, Gallo PM, Hooper KM, Corradetti C, Ganea D, Caricchio R, Gallucci S. The cytokine network type I IFN-IL-27-IL-10 is augmented in murine and human lupus. J Leukoc Biol. 2019 10; 106(4):967-975.
-
Muralidharan S, Lim A, Catalano D, Mandrekar P. Human Binge Alcohol Intake Inhibits TLR4-MyD88 and TLR4-TRIF Responses but Not the TLR3-TRIF Pathway: HspA1A and PP1 Play Selective Regulatory Roles. J Immunol. 2018 04 01; 200(7):2291-2303.
-
Seliga A, Lee MH, Fernandes NC, Zuluaga-Ramirez V, Didukh M, Persidsky Y, Potula R, Gallucci S, Sriram U. Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation. Front Immunol. 2018; 9:156.
-
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
-
Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017 May; 76(5):847-855.e5.
-
Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE. CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. J Invest Dermatol. 2017 04; 137(4):982-985.